度易达®(度拉糖肽注射液)
本页包括过去3年在同行评审期刊上发表的礼来发起的临床试验。
以下列表仅限于与已批准使用的产品相关的出版物,
可能是非适应症的。(请参见产品完整处方信息链接)
如果您对下面未列出的礼来研究有任何疑问,或希望获得本页期刊出版物的电子版,
请联系下面的礼来客户服务中心以获得进一步的帮助。
中国健康受试者和2 型糖尿病 患者单次或多次给药后度拉糖肽的药代动力学、药效学和安全性:一项随机、安慰剂对照、I 期研究
Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide after Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study
发表日期:2021-11-07
每周一次的度拉糖肽治疗青少年 2 型糖尿病
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
发表日期:2022-08-04
美国 2 型糖尿病患者度拉糖肽起始时机与治疗模式和临床结果的关联
Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States
发表日期:2022-06-01
度拉糖肽在不同基线 HbA1c 亚组中的疗效和安全性结果:REWIND 试验的事后分析
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
发表日期:2022-05-11
度拉糖肽高剂量(3.0 mg和 4.5 mg)在心血管疾病风险增加的 2 型糖尿病受试者中对心血管疾病风险因素的影响:AWARD-11 研究的事后分析
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study
发表日期:2022-05-11
无论糖尿病病程、微血管疾病和 BMI ,度拉糖肽治疗患者 HbA1c下降 :来自 REWIND 试验的事后分析
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
发表日期:2022-01-18
度拉糖肽与 2 型糖尿病患者发生心房颤动或心房扑动:来自 REWIND 随机试验的事后分析
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
发表日期:2022-01-04
度拉糖肽在中国 2 型糖尿病种的疗效和不同血糖模式:3 期 AWARD-CHN2 试验的事后分析
Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
发表日期:2021-12-06
每周一次度拉糖肽治疗中国2型糖尿病患者的胰腺安全性:针对潜在影响因素的亚组分析
Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
发表日期:2021-09-28
根据蛋白尿状态列出的2型糖尿病(T2D)和中度至重度CKD患者中,度拉糖肽(DU)与甘精胰岛素(IG)的慢性肾病(CKD)结局:AWARD-7探索性分析
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis
发表日期:2021-02-25
度拉糖肽在老年患者中的疗效和安全性:REWIND试验的事后分析
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
发表日期:2021-02-04
GLP-1受体激动剂心血管结局试验期间HbA1c变化和糖尿病视网膜病变:荟萃分析和荟萃回归
HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
发表日期:2020-12-21
在基线体重指数较低的中国2型糖尿病成人患者中度拉糖肽每周一次给药的疗效和安全性
Efficacy and safety of once‐weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index
发表日期:2020-12-16
REWIND试验中接受度拉糖肽治疗的有心血管风险因素的2型糖尿病患者的心血管或致死性事件总数-事后分析
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
发表日期:2020-11-25
在接受度拉糖肽伴或不伴基线二甲双胍治疗的已确定或高风险冠状动脉血管疾病的糖尿病患者中,心血管结局相似
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
发表日期:2020-11-16
度拉糖肽每周一次在东亚2型糖尿病患者中的疗效和安全性:按潜在影响因素进行的亚组分析
Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors
发表日期:2020-11-08
每周一次度拉糖肽治疗中国老年2型糖尿病患者的疗效和安全性:AWARD-CHN研究的事后分析
Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
发表日期:2020-08-28
在中国2型糖尿病患者中评价度拉糖肽每周一次治疗的胃肠道不良事件特征:两项随机试验的事后汇总分析
Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials
发表日期:2020-07-04
度拉糖肽对2型糖尿病患者认知功能下降的影响:一项REWIND试验的探索性分析
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
发表日期:2020-06-17
度拉糖肽中国上市后安全性研究(TRUST-CHN)研究设计及2型糖尿病患者的基线特征
Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)
发表日期:2022-05-18
在1年随访中,注射用度拉糖肽的依从性和持久性高于注射用司美格鲁肽:来自美国临床实践的数据
Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice
发表日期:2022-03-06
度拉糖肽和利拉鲁肽在2型糖尿病患者中的健康结局的真实观察性前瞻性研究(TROPHIES):基线患者报告的结局
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
发表日期:2020-09-03